Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30921523 | 1.00 | CA2 (0.43) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL29482089 | 0.86 | LMNA (0.48) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL523821 | 0.86 | LMNA (0.48) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL1700634 | 0.86 | CA2 (0.43) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL20699431 | 0.86 | GPR119 (0.41) | CA2CA12CA1MAPTALDH1A1 | |
| SCHEMBL1700952 | 0.83 | LMNA (0.45) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL1700453 | 0.82 | SOS1 (0.46) | CA2CA12CA1CA9IRAK4 | |
| SCHEMBL19183113 | 0.82 | LMNA (0.42) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL1701837 | 0.82 | MAPT (0.41) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL2477245 | 0.81 | MAPT (0.40) | CA2CA12CA1CA9VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20250051329-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-112661751-B | Heterocyclic compounds as BCL-2 inhibitors | 南京天印健华医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA2 2352/4885CA12 1100/4885CA1 1290/4885 |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA2 2479/4885CA12 1381/4885CA1 1508/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | CA2 2436/4885CA12 2690/4885CA1 2547/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA2 2479/4885CA12 1381/4885CA1 1508/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | CA2 3835/4885CA12 3980/4885CA1 2319/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | CA2 3015/4885CA12 2561/4885CA1 2706/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | CA2 2436/4885CA12 2690/4885CA1 2547/4885 |
| US-20250051329-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | CA2 2629/4885CA12 3754/4885CA1 2188/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA2 2352/4885CA12 1100/4885CA1 1290/4885 |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA2 2352/4885CA12 1100/4885CA1 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.